Latest BLRX reports update at 2024-04-27: 2023 ∙ 2022 ∙ 2021
  1. Home
  2. Stock quotes
  3. BioLineRx Ltd.
  4. Financial Statements
BioLineRx Ltd. logo
BioLineRx Ltd. BLRX
$ 0.61 6.31%
mail-toReport an Error

BioLineRx Ltd. Financial Statements 2011-2024 | BLRX

Annual Financial Statements BioLineRx Ltd.

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

 - - 1.35 B 42.5 M 22 M 47.8 M 98.1 M 59 M 52.9 M 58.4 M 65.7 M 77.1 M 47.1 M

Shares

 - - 663 M 16.9 M 9.76 M 7.24 M 6 M 3.74 M 3.43 M 2.16 M 1.5 M 1.13 M 824 K

Historical Prices

 0.72 1.37 2.04 2.52 2.25 6.6 16.4 13.8 19.5 24.3 42.1 38 47.5

Net Income

 - - -27.1 M -30 M -25.4 M -23 M -24.4 M -15.8 M -14.4 M -10.2 M -17.6 M -20.4 M -13.2 M

Revenue

 4.8 M - - - - - - - - - - - -

Cost of Revenue

 - - - - - - - - - - - - -

Gross Profit

 - - - - - - - - - - - - -

Operating Income

 - - -24.8 M -22.9 M -28.1 M -25.6 M -25.2 M -16.5 M -16.2 M - - - -

Interest Expense

 2.14 M 1.79 M 984 K 1.47 M - - - - - - - - -

EBITDA

 - - -24.8 M -22.9 M -28.1 M -25.6 M -25.2 M -16.5 M -16.2 M -15.8 M -17.5 M -21.8 M -15 M

Operating Expenses

 - - - - 28.1 M 25.6 M 25.2 M 16.5 M 16.2 M 15.9 M 17.6 M 21.8 M 15.4 M

General and Administrative Expenses

 - - 4.31 M 3.84 M 3.37 M 3.87 M 3.57 M 3.47 M 3.22 M 3.06 M 3.33 M 3.23 M 3.34 M

All numbers in USD currency

Quarterly Income Statement BioLineRx Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 - - - - - - 669 M - - - 220 M - - - 145 M - - - 107 M - - - 94.5 M - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

 - - - - - - -6.84 M - - - -6.77 M - - - -5.48 M - - - -4.79 M - - - -4.9 M - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

 - - - - - - -6.51 M - - - -5.57 M - - - -6.48 M - - - -5.73 M - - - -5.19 M - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

 - - - - - - -6.51 M - - - -5.57 M - - - -6.48 M - - - -5.73 M - - - -5.19 M - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

 - - - - - - 1.04 M - - - 744 K - - - 949 K - - - 883 K - - - 844 K - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency